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Abstract
Background: Black women living in southern states have the highest breast cancer mortality rate in the United States. The
prognosis of de novo metastatic breast cancer is poor. Given these mortality rates, we are the first to link nationally
representative data on breast cancer mortality hot spots (counties with high breast cancer mortality rates) with cancer
mortality data in the United States and investigate the association of geographic breast cancer mortality hot spots with de
novo metastatic breast cancer mortality among Black women. Methods: We identified 7292 Black women diagnosed with de
novo metastatic breast cancer in Surveillance, Epidemiology, and End Results (SEER). The county-level characteristics were
obtained from 2014 County Health Rankings and linked to SEER. We used Cox proportional hazards models to calculate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for mortality between hot spot and non–hot spot counties.
Results: Among 7292 patients, 393 (5.4%) resided in breast cancer mortality hot spots. Women residing in hot spots had
similar risks of breast cancer–specific mortality (aHR ¼ 0.99, 95% CI ¼ 0.85 to 1.15) and all-cause mortality (aHR ¼ 0.97, 95% CI
¼ 0.84 to 1.11) as women in non–hot spots after adjusting for individual and tumor-level factors and treatments. Additional
adjustment for county-level characteristics did not impact mortality. Conclusion: Living in a breast cancer mortality hot spot
was not associated with de novo metastatic breast cancer mortality among Black women. Future research should begin to
examine variation in both individual and population-level determinants, as well as in molecular and genetic determinants
that underlie the aggressive nature of de novo metastatic breast cancer.

Breast cancer is the most common cancer among women in the
United States, with the highest incidence in White women. Yet,
racial and ethnic disparities in breast cancer mortality rates persist (1,2). In the most recent period (2013-2017), the breast cancer mortality rate was 40% higher in Black women (28.4 per
100 000) vs White women (20.3 per 100 000) (2). Across all racial
and ethnic groups, the stage of diagnosis is associated with survival. For women diagnosed with American Joint Committee on
Cancer (AJCC)–defined stage I breast cancer, the expected 5-year
breast cancer–specific survival rate is more than 96% (2).
However, 5-year breast cancer–specific survival rates decrease
as patients are diagnosed beyond AJCC stage I (3).

Approximately 5%-10% of all new breast cancer diagnoses
are AJCC stage IV, also called de novo metastatic breast cancer
(4,5). The overall prognosis for de novo metastatic breast cancer
is poor, with the median overall survival ranging from 19 to
28 months (5,6); however, there have been recent improvements
(4). These improvements may be partly attributed to advances
in the molecular-level characterizations of breast cancer, use of
hormone therapy, and targeted treatment strategies (7). Despite
these improvements, breast cancer survival remains low among
Black patients in late-stage distant metastatic breast cancer,
according to The American Cancer Society’s "Breast Cancer
Facts and Figures 2019-2020” (8).
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1,007,821 female patients with known age,
first primary breast cancer diagnosed from
1990 to 2016 in SEER 18 registries

7,292 Eligible patients for final analysis
Figure 1. Flowchart of eligible individuals, SEER 18 registries 1990-2016. SEER ¼ Surveillance, Epidemiology, and End Results.

As seen across racial and ethnic groups, geographic disparities in breast cancer outcomes exist across the United States
(9). Historical factors, such as Jim Crow laws, housing and zoning policies, and migration patterns, have created swaths of racially segregated areas that still exist today (10,11). There has
been an emergence of interdisciplinary researchers interested
in the intersection of race and geographical location on health
outcomes. Disease-specific geographic hot spots are the spatial
aggregation of cases in an identifiable subpopulation based on
geographic excess risks (12). A breast cancer mortality hot spot
is a county identified as high risk for breast cancer mortality.
Hot spots of breast cancer mortality among Black women were
found primarily in rural southern counties near the Mississippi
River and counties in the northern coastal North Carolina and
southern Virginia areas of the United States (13).
However, to our knowledge, no study has investigated associations between geographic hot spots and mortality among
Black women with de novo metastatic breast cancer. Thus, we
are the first to link nationally representative data on breast cancer mortality hot spots with incident-based mortality data on
de novo metastatic breast cancer in the United States and examine the association of geographic breast cancer mortality hot
spots with de novo metastatic breast cancer mortality among
Black women. Understanding this association can help medical
and public health experts tailor programs and maximize resources to improve survivorship rates for this vulnerable group.

Methods
Study Design and Data
Data for this study were obtained from the Surveillance,
Epidemiology, and End Results (SEER) 18 Registries Custom Data
and the Centers for Disease Control and Prevention’s underlying
causes of death file (14,15). This study was considered exempt
by the institutional review board of Washington University
School of Medicine because we used existing secondary data
that are publicly available and nonidentifiable.

18 database (16). Female patients with known age and diagnosed with first primary breast cancer from 1990 to 2016 were
potentially eligible for this study (n ¼ 1 007 821; Figure 1).
Women were excluded if they had no distant metastases or unknown metastatic information (n ¼ 959 191); lacked microscopic
confirmation (n ¼ 2369); were without active follow-up (n ¼ 65);
lived in Alaska, Hawaii, or unknown hot spot counties (n ¼ 843);
were not non-Hispanic Blacks (hereinafter, Blacks) (n ¼ 38 061).
Thus, our sample consisted of 7292 Black women with de novo
metastatic breast cancer for final analysis. Individual demographic and clinical characteristics in SEER were used as potential covariates including age at diagnosis, year of diagnosis,
marital status, tumor histology, tumor grade, hormone receptor
status, the first course of treatments (surgery, radiation, and
chemotherapy), and SEER registry. In brief, patients in metro
counties with codes 1-3 were classified as urban, and all nonmetro counties with codes 4-9 were classified as rural.

Hot Spots of Breast Cancer Mortality Among Black
Women
Although a variety of approaches exist for spatial disease clustering, we used the aggregation of 3 separate local and global
spatial clustering methods to identify counties that were hot
spots for breast cancer mortality. This cluster identification
method has been described in detail previously (13,17,18), and
the use of this conservative approach helps avoid spurious
results obtained from simply relying on one method. Briefly, we
categorized county-level breast cancer mortality into 2 groups—
hot spots or non–hot spots—based on a statistically significant
higher observed vs expected breast cancer mortality rate. Hot
spot counties are those identified as high risk for breast cancer
mortality using all 3 approaches: 1) fifth quintile of smoothed
Empirical Bayes breast cancer mortality rates, 2) high-high clusters using local indicators of spatial association, and 3) as a hot
spot defined by Getis-Ord Gi* statistic (19,20). All other contiguous US counties were categorized as non–hot spots.

County-Level Characteristics
Study Population
We used “case listing” function through SEER*Stat software (version 8.3.6) to export potential cases for analysis from the SEER

To obtain characteristics on county-level demographic, socioeconomic, and health availability and/or community resources,
cases identified in SEER were linked with county-level data
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1,000,529 Excluded
959,191 No distant metastases or unknown
metastatic information
2,369 Not microscopic confirmed
65 Not active follow-up
843 Women living in Alaska and Hawaii,
and unknown hot spot counties
38,061 Not non-Hispanic Blacks
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Statistical Analysis
We compared bivariate differences in participant and tumor
characteristics, county-level characteristics, and survival time
in hot spots vs non–hot spot counties using v2, analysis of variance, or Wilcoxon rank-sum tests as appropriate. We compared
hot spots vs non–hot spot counties and presented the medians
and interquartile ranges for the county-level characteristics because of the nonparametric distribution of continuous variables
(Table 2). Because of the large number of counties examined,
there were many associations considered statistically significant at a equals 0.05. Therefore, to observe the magnitude of the
correlation between hot spots and county-level characteristics,
we additionally examined the correlation of county-level characteristics with residents at diagnosis in county-level hot spots
of breast cancer mortality using a Spearman correlation (q, positive values indicate positive correlation, and negative values indicate negative correlation). We examined the proportional
hazards assumption for breast cancer–specific survival and
overall survival by Schoenfeld residuals and by graphically
assessing the log-log plots of survival. Therefore, we used Cox
proportional hazards models to assess hazard ratios (HR) and
95% confidence intervals (CIs) for time to death from de novo
metastatic breast cancer comparing hot spot and non–hot spot
residence. Survival time was estimated from the date of diagnosis to the last date of follow-up or death. We performed a sequential model-building approach to examine possible
confounders on the association between hot spot residence and
mortality. The contribution of individual-level covariates, tumor
factors, and treatments for multivariable models was assessed
by a measure of the relative change in hazard ratios (22).
Multivariable-adjusted model 1 was adjusted for individuallevel factors (age, year of diagnosis, marital status, and SEER
registries), tumor-level factors (tumor histology, tumor grade,
and hormone receptor status), and treatments (surgery, chemotherapy, and radiation therapy). Multivariable-adjusted model 2
was adjusted for all factors in multivariable-adjusted model 1
with additional county-level factors that were associated with
hot spots in a moderate Spearmen correlation (q j0.20j). We
performed statistical analyses using SAS version 9.4. All

statistical tests were 2-sided, and P values less than .05 were
considered statistically significant.

Results
Descriptive Characteristics
Among 7292 Black women diagnosed with de novo metastatic
breast cancer over the 27-year study period, approximately 5.4%
(n ¼ 393) women resided in hot spot counties at their diagnosis
(Table 1). The mean age of all patients was 58.47 years and did
not statistically significantly differ by hot spot classification
(Table 1). Compared with women living in non–hot spot counties, women residing in hot spot counties were more likely to be
diagnosed between 2010 and 2016 (52.9% vs 40.8%), more likely
to reside in rural areas (18.3% vs 6.1%), more likely to have ductal histology of breast tumor (73.5% vs 67.7%), and more likely to
have grade 2 tumor (30.5% vs 23.1%) (Table 1).
County-level characteristics by hot spot classification are
presented in Table 2. Black women living in hot spot counties
with de novo metastatic breast cancer diagnosis were statistically significantly more likely than women living in non–hot
spot counties to reside in areas with greater proportions of
White residents (59.3% vs 46.6%), a greater prevalence of adult
obesity (33.5% vs 26.9%), a greater prevalence of smoking (20.8%
vs 14.8%), more physical inactivity (32.0% vs 24.1%), and a
greater proportion of rural residents (13.2% vs 1.1%). Moreover,
hot spot counties were statistically significantly less likely than
non–hot spot counties to have greater proportions of Hispanic
(5.0% vs 9.1%), to be areas with college completion rates (22.8%
vs 29.9%), to have access to exercise opportunity (57.1% vs
92.5%), and less unemployment (7.5% vs 9.6%).

Hot Spot Residence and Mortality
Over a median of 14 months, 5995 women (82.2%) died, including 5363 women (73.5%) from breast cancer (Table 3). Patients
who resided in a breast cancer mortality hot spot were not at increased risk of death from de novo metastatic breast cancer
mortality (adjusted hazard ratios [aHR] ¼ 0.99, 95% CI ¼ 0.86 to
1.13) compared with women living in non–hot spot counties,
while controlling for individual-level factors, tumor-level factors, and treatments in multivariable model 1 (Table 3). We observed similar results after additionally adjusting for countylevel proportions, including completed college education, population with obesity, current smoking status, physically inactive,
and access to exercise opportunities, in multivariable model 2.
Similarly, in fully adjusted models, women residing in hot spots
had similar risks of breast cancer–specific mortality (aHR ¼ 0.99,
95% CI ¼ 0.85 to 1.15) and all-cause mortality (aHR ¼ 0.97, 95% CI
¼ 0.84 to 1.11) as women in non–hot spots after adjusting for individual and tumor-level factors and treatments (Table 3).
Furthermore, the lack of association persisted when we evaluated different segments of follow-up time after disease diagnosis using piecewise Cox proportional hazards model controlling
for full covariates in model 2 (0-2 years aHR ¼ 1.05, 95% CI ¼ 0.90
to 1.22; 2-4 years aHR ¼ 1.20, 95% CI ¼ 0.90 to 1.61; 4-6 years aHR
¼ 1.23, 95% CI ¼ 0.74 to 2.03; 6 years aHR ¼ 0.95, 95% CI ¼ 0.43
to 2.10; data not shown). Individual-level factors reduced the
hazard ratio by 3.2%, treatments reduced the hazard ratio by
4.2%, and county-level factors reduced the hazard ratio by 1.6%,
whereas tumor-level factors increased the hazard ratio by 2.7%.
In total, adjustment for all covariates explained 6.2% of the
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from the 2014 County Health Rankings (CHR) and the 2014
American Community Survey (ACS) based on county Federal
Information Processing Standards codes (21). The CHR and ACS
comprise nationally representative data collected from a sample of the total noninstitutionalized population aged 18 years
and older residing in households. The CHR database uses several survey samples to provide generalizable estimates of
county-level factors, and the ACS provides aggregated estimates
for demographic statistics over 5 years (2014 ACS, years 20102014). From CHR and ACS, we considered estimates of the
county-level proportions of race and ethnicity, completed college, household income, obesity, smoking, excessive drinking,
persons who could not see a doctor because of costs, limited access to healthy foods, mammography screening, physical inactivity, access to exercise opportunities, unemployment,
uninsured, the ratio of primary care physicians per 100 000 persons, and rurality. County-level rurality was evaluated as a dichotomous variable (rural-urban) using 2010 Rural-Urban
Commuting Area classifications, where urban areas were defined as population centers with more than 50 000þ residents,
and rural and nonurban areas were defined as towns or small
cities with population centers with fewer than 50 000 residents.
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Table 1. Comparison of participant and tumor characteristics by breast cancer mortality hot spot classification among 7292 Black women diagnosed as de novo metastatic breast cancer from SEER 18 registries, 1990-2016
Breast cancer mortality hot spot counties
Total (n ¼ 7292)

Hot spot (n ¼ 393; 5.4%)

Non–hot spot (n ¼ 6899; 94.6%)

Pb

58.47 (0.17)

58.33 (0.72)

58.48 (0.17)

.95

706 (9.7)
1246 (17.1)
1980 (27.2)
1699 (23.3)
1105 (15.2)
556 (7.6)

39 (9.9)
65 (16.5)
101 (25.7)
102 (26.0)
54 (13.7)
32 (8.1)

667 (9.7)
1181 (17.1)
1879 (27.2)
1597 (23.2)
1051 (15.2)
524 (7.6)

.80

1011 (13.9)
3256 (44.7)
3025 (41.5)
23.72 (0.37)

3 (0.8)
182 (46.3)
208 (52.9)
21.59 (1.34)

1008 (14.6)
3074 (44.6)
2817 (40.8)
23.84 (0.38)

<.001

2582 (35.4)
1940 (26.6)
2383 (32.7)
387 (5.3)

134 (34.1)
100 (25.5)
131 (33.3)
28 (7.1)

2448 (35.5)
1840 (26.7)
2252 (32.6)
359 (5.2)

.38

6801 (93.3)
491 (6.7)

321 (81.7)
72 (18.3)

6480 (93.9)
419 (6.1)

4960 (68.0)
541 (7.4)
233 (3.2)
1558 (21.4)

289 (73.5)
31 (7.9)
10 (2.5)
63 (16.0)

4671 (67.7)
510 (7.4)
223 (3.2)
1495 (21.7)

.04

251 (3.4)
1716 (23.5)
3236 (44.4)
135 (1.9)
1954 (26.8)

17 (4.3)
120 (30.5)
159 (40.5)
7 (1.8)
90 (22.9)

234 (3.4)
1596 (23.1)
3077 (44.6)
128 (1.9)
1864 (27.0)

.01

3913 (53.7)
1993 (27.3)
1386 (19.0)
2541 (34.9)
2339 (32.1)
4141 (56.8)

205 (52.2)
116 (29.5)
72 (18.3)
136 (34.6)
111 (28.2)
224 (57.0)

3708 (53.8)
1877 (27.2)
1314 (19.1)
2405 (34.9)
2228 (32.3)
3917 (56.8)

.61

Age at diagnosis, mean (SE), y
Age at diagnosis, No. (%), y
<40
40-49
50-59
60-69
70-79
80
Year of diagnosis, No. (%)
1990-1999
2000-2009
2010-2016
Survival time, months, mean (SE)
Marital status, No. (%)
Single or never married
Married or domestic partner
Divorced, separated, or widowed
Unknown
Urban or rural residence, No. (%)
Urban
Rural
Tumor histology, No. (%)
Ductal
Lobular
Mixed ductal and lobular
Other histology
Tumor grade, No. (%)
1 (well differentiated)
2 (moderately differentiated)
3 (poorly differentiated)
4 (undifferentiated)
Unknown
Hormone receptor status, No. (%)
Positive (ERþ or PRþ)
Negative (ER- and PR-)
Unknown
Surgery, No. (%), yes
Radiation, No. (%), yes
Chemotherapy, No. (%), yes

.56

<.001

.18
.09
.93

a

Patients residing in counties with high breast cancer mortality (fulfilling all 3 criteria for geographic clustering). ER ¼ estrogen receptor; PR ¼ progesterone receptor;

SEER ¼ Surveillance, Epidemiology, and End Results.
b

Statistical significance determined using v2 tests for categorical variables, analysis of variance (ANOVA) for parametric continuous variables, or Wilcoxon rank-sum
tests for nonparametric continuous variables.

breast cancer–specific survival across hot spot classification
(Supplementary Table 2, available online). Additionally, the hazard ratios for overall mortality were similar to findings for
breast cancer–specific mortality (Table 3).
For comparison purposes, we examined the hazard ratios
and 95% confidence intervals for all women in SEER 18 database
from 1990 to 2016 (Supplementary Table 3, available online).
Among 45 353 women, 30 967 were Whites (68.3%), 7292 were
Blacks (16.1%), 4433 were Hispanic (9.8%), and 2661 were other
races (5.9%). For this analysis, we identified 80 of 3108 (2.6%)
counties as hot spots for breast cancer mortality for all women
as our previous published article in mapping hot spots of breast
cancer mortality in the United States (13). Among all women,
we observed that residence in breast cancer mortality hot spots

was not associated with increased risk of de novo metastatic
breast cancer death (aHR ¼ 1.06, 95% CI ¼ 0.91 to 1.24;
Supplementary Table 4, available online) after controlling for
individual-level factors (age, race, marital status, and SEER registry). Compared with White women, Black women have a 30%
increased risk of breast cancer–specific death (aHR ¼ 1.30, 95%
CI ¼ 1.26 to 1.34; Supplementary Table 4, available online).

Discussion
In this study, we are the first to link nationally representative
data on breast cancer mortality hot spots with incident-based
mortality data on de novo metastatic breast cancer among 7292
Black women in the United States. We observed that Black
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Table 2. County-level characteristics by breast cancer mortality hot spot classification among 7292 Black women from SEER 18 registries, 19902016, linked with 2014 American Community Survey and County Health Rankings county-level data
Breast cancer mortality hot spot counties
a

Hot spot (n ¼ 393; 5.4%)
Median (IQR)d

Non–hot spot (n ¼ 6899; 94.6%)
Median (IQR)d

Pb

qc

59.3 (55.6-65.9)
26.0 (18.5-36.6)
5.0 (1.9-12.8)
22.8 (13.3-25.8)
20.3 (16.8-26.8)
33.5 (32.0-36.4)
20.8 (19.2-21.1)
14.4 (12.0-17.2)
16.2 (13.6-17.6)
5.0 (4.4-11.5)
61.4 (57.1-61.8)
32.0 (27.8-32.9)
57.1 (40.2-88.8)
7.5 (6.2-10.6)
26.6 (19.4-27.9)
6.7 (3.8-8.6)
13.2 (1.6-24.2)

46.6 (33.4-55.4)
24.0 (8.4-40.0)
9.1 (5.3-22.6)
29.9 (21.7-39.4)
18.5 (16.0-26.0)
26.9 (22.9-33.6)
14.8 (12.3-20.9)
16.0 (15.0-17.7)
15.6 (13.5-18.1)
4.0 (1.6-7.7)
59.3 (57.5-62.0)
24.1 (19.6-27.7)
92.5 (81.2-96.8)
9.6 (8.6-10.9)
24.5 (21.5-28.5)
7.1 (6.5-9.4)
1.1 (0.6-5.9)

<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
.07
<.001
<.001
<.001
.59
.42
<.001

0.17
0.04
0.14
0.21
0.08
0.23
0.20
0.05
0.07
0.16
0.02
0.32
0.25
0.19
0.01
0.12
0.15

% NH-White
% NH-Black
% Hispanic
% Completed college
% Household income <$20,000
% Obesity
% Smoking
% Excessive drinking
% Could not see doctor because of cost
% Limited access to healthy foodse
% Mammography screening
% Physical inactivity
% Access to exercise opportunities
% Unemployment
% Uninsured
PCP per 100 000 persons
% Nonurban (rural)
a

Patients residing in counties with high breast cancer mortality (fulfilling all 3 criteria for geographic clustering). IQR ¼ interquartile range; NH ¼ non-Hispanic; PCP ¼

primary care physicians; SEER ¼ Surveillance, Epidemiology, and End Results.
b
Statistical significance determined using v2 tests for categorical variables or Wilcoxon rank-sum tests for nonparametric continuous variables.
c

Spearman correlation with being a county-level breast cancer mortality hot spot.

d

Median and IQR.

e

Index that ranges from 0 (worst) to 10 (best), depending on the access to healthy foods by considering the distance an individual lives from a grocery store or
supermarket.

Table 3. Multivariable hazard ratios for breast cancer–specific mortality and overall mortality among 7292 Black women diagnosis with de
novo metastatic breast cancer from SEER 18 registries, 1990-2016
Breast cancer–specific mortality
Breast cancer
mortality hot
spot
Non–hot spot
Hot spot

Overall mortality

No. of breast cancer
No. of all-cause
deaths/No. of women
Model 1
Model 2
Model 3 deaths/No. of women Model 1
Model 2
Model 3
(%)a
(%)a
HR (95% CI)b HR (95% CI)c HR (95% CI)d
HR (95% CI)b HR (95% CI)c HR (95% CI)d
5076/6899 (73.6)
287/393 (73.0)

Referent
Referent
Referent
0.99 (0.86 to 0.97 (0.85 to 0.99 (0.85 to
1.13)
1.11)
1.15)

5678/6899 (82.3)
317/393 (80.7)

Referent
Referent
Referent
0.98 (0.86 to 0.96 (0.84 to 0.97 (0.84 to
1.11)
1.09)
1.11)

a

Numbers presented were from the Black women cohort (n ¼ 7292). CI ¼ confidence interval; HR ¼ hazard ratio; SEER ¼ Surveillance, Epidemiology, and End Results.

b

Model 1 was adjusted for age at diagnosis, year of diagnosis, marital status, tumor histology, tumor grade, hormone receptor status, treatments (surgery, radiation,
and chemotherapy), and SEER registry.

c

Model 2 was additionally adjusted for county-level proportions for completed college education, population with obesity, current smoking status, physically inactive,

and access to exercise opportunities in addition to model 1.
d

Model 3 was adjusted for all individual-level, tumor-level, and county-level variables.

women diagnosed with de novo metastatic breast cancer had
similar risk of death regardless of residence in county-level hot
spots of breast cancer mortality.
The incidence of distant-stage breast cancer has increased
over the past few decades (23). This increase may be partly
explained by the more complete staging of advanced tumors
(24) and increased use of advanced imaging to detect asymptomatic metastases (8). The prevalence of metastatic breast
cancer in the United States from 1990 to 2020 was estimated
that there will be 168 292 women living with metastatic breast
cancer by 2020 (25). Evidence indicated that the odds of latestage breast cancer among Black women were 43% higher
when compared with their White counterparts (26) and demonstrated a widening racial and ethnic disparity gap in breast

cancer stage at diagnosis in the recent decade (27-31). Further,
studies using SEER data suggested that Black women may
have up to a 45% increased risk of death from HER2-positive
metastatic breast cancers when compared with White women
(32). In comparison, another report of data from 2 breastspecific practices suggested that race and ethnicity may not
contribute to the survival of patients diagnosed with de novo
metastatic breast cancer (33). Differences in age distribution,
race and ethnicity, comorbidities, and tumor factors could
lead to survival differences between large SEER data and small
practices. These mixed and limited studies support our exploration of breast cancer mortality hot spots and de novo metastatic breast cancer mortality among Black women, despite
our null findings.
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well as in molecular and genetic determinants that underlie the
aggressive nature of de novo metastatic breast cancer.
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